非小细胞肺癌免疫治疗的临床影响因素

摘要/Abstract

摘要：

在非小细胞肺癌(NSCLC)的治疗中,以免疫检查点抑制剂为代表的免疫疗法快速发展,明确NSCLC免疫治疗的影响因素是精准化治疗的前提。在晚期NSCLC的免疫治疗过程中,老年患者能从中获得一定疗效;男性患者在单药治疗中获益更多;类固醇激素在用于肿瘤引起的相关症状时为患者不良预后因素;发生免疫相关不良事件为良性预后因素,而驱动基因突变、抗生素的使用则会降低免疫治疗疗效。

关键词:癌,非小细胞肺,预后,抗菌药,免疫检查点抑制剂

Abstract:

In the treatment of non-small cell lung cancer (NSCLC), immunotherapies represented by immune checkpoint inhibitors are developing rapidly. It is the premise of precise treatment to clarify the influencing factors of NSCLC immunotherapy. In the course of immunotherapy for advanced NSCLC, elderly patients can obtain specific effect from immunotherapy; male patients benefit more from monotherapy; when steroid hormones are used for related symptoms caused by tumors, they are poor prognostic factors for patients. The occurrence of immune-related adverse events is a favorable prognostic factor while driving gene mutations and the use of antibiotics will reduce the efficacy of immunotherapy.

Key words:Carcinoma,non-small cell lung,Prognosis,Anti-bacterial agents,Immune checkpoint inhibitor

刘超星, 严雪冰, 杨梦雪, 毛海燕, 童建东. 非小细胞肺癌免疫治疗的临床影响因素[J]. 国际肿瘤学杂志, 2021, 48(12): 751-754.

Liu Chaoxing, Yan Xuebing, Yang Mengxue, Mao Haiyan, Tong Jiandong. Clinical influencing factors of immunotherapy for non-small cell lung cancer[J]. Journal of International Oncology, 2021, 48(12): 751-754.

参考文献31

[1]	Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO cinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv192-iv237. DOI: 10.1093/annonc/mdy275.
[2]	Kashima J, Kitadai R, Okuma Y. Molecular and morphological profiling of lung cancer: a foundation for "next-generation" pathologists and oncologists[J]. Cancers (Basel), 2019,11(5):599. DOI: 10.3390/cancers11050599.
[3]	Cao J, Li J, Yang X, et al. Transcriptomics analysis for the identification of potential age-related genes and cells associated with three major urogenital cancers[J]. Sci Rep, 2021,11(1):641. DOI: 10.1038/s41598-020-80065-y.
[4]	Corbaux P, Maillet D, Boespflug A, et al. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting[J]. Eur J Cancer, 2019,121:192-201. DOI: 10.1016/j.ejca.2019.08.027.
[5]	Spigel DR, McCleod M, Jotte RM, et al. Safety, Efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153)[J]. J Thorac Oncol, 2019,14(9):1628-1639. DOI: 10.1016/j.jtho.2019.05.010.
[6]	Nishijima TF, Muss HB, Shachar SS, et al. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis[J]. Cancer Treat Rev, 2016,45:30-37. DOI: 10.1016/j.ctrv.2016.02.006.
[7]	Elias R, Giobbie-Hurder A, McCleary NJ, et al. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis[J]. J Immunother Cancer, 2018,6(1):26. DOI: 10.1186/s40425-018-0336-8.
[8]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015,373(2):123-135. DOI: 10.1056/NEJMoa1504627.
[9]	Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase Ⅲ trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer[J]. J Clin Oncol, 2021,39(7):723-733. DOI: 10.1200/JCO.20.01605.
[10]	Kanjanapan Y, Day D, Wang L, et al. Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities[J]. Cancer, 2019,125(8):1341-1349. DOI: 10.1002/cncr.31999.
[11]	Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis[J]. Lancet Oncol, 2018,19(6):737-746. DOI: 10.1016/S1470-2045(18)30261-4.
[12]	Reed JP, Devkota S, Figlin RA. Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer[J]. Ann Transl Med, 2019,7(Suppl 8):S309. DOI: 10.21037/atm.2019.10.27.
[13]	Passaro A, Attili I, Morganti S, et al. Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: a critical review of published data[J]. Cancer Treat Rev, 2020,89:102085. DOI: 10.1016/j.ctrv.2020.102085.
[14]	Galli G, Triulzi T, Proto C, et al. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer[J]. Lung Cancer, 2019,132:72-78. DOI: 10.1016/j.lungcan.2019.04.008.
[15]	Ouaknine Krief J, Helly de Tauriers P, Dumenil C, et al. Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab[J]. J Immunother Cancer, 2019,7(1):176. DOI: 10.1186/s40425-019-0658-1.
[16]	Lurienne L, Cervesi J, Duhalde L, et al. NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis[J]. J Thorac Oncol, 2020,15(7):1147-1159. DOI: 10.1016/j.jtho.2020.03.002.
[17]	Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018,359(6371):97-103. DOI: 10.1126/science.aan4236.
[18]	Haanen JBAG, Carbonnel F, Robert C , et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(suppl_4): iv264-iv266. DOI: 10.1093/annonc/mdy162.
[19]	Fucà G, Galli G, Poggi M, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors[J]. ESMO Open, 2019,4(1):e000457. DOI: 10.1136/esmoopen-2018-000457.
[20]	Petrelli F, Signorelli D, Ghidini M, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Cancers (Basel), 2020,12(3):546. DOI: 10.3390/cancers12030546.
[21]	Ricciuti B, Dahlberg SE, Adeni A, et al. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer recei-ving baseline corticosteroids for palliative versus nonpalliative indications[J]. J Clin Oncol, 2019,37(22):1927-1934. DOI: 10.1200/JCO.19.00189.
[22]	Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018,379(21):2040-2051. DOI: 10.1056/NEJMoa-1810865.
[23]	Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors[J]. J Immunother Cancer, 2019,7(1):306. DOI: 10.1186/s40425-019-0805-8.
[24]	Grangeon M, Tomasini P, Chaleat S, et al. Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer[J]. Clin Lung Cancer, 2019,20(3):201-207. DOI: 10.1016/j.cllc.2018.10.002.
[25]	Ricciuti B, Genova C, De Giglio A, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis[J]. J Cancer Res Clin Oncol, 2019,145(2):479-485. DOI: 10.1007/s00432-018-2805-3.
[26]	Akamatsu H, Murakami E, Oyanagi J, et al. Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer[J]. Oncologist, 2020,25(4):e679-e683. DOI: 10.1634/theoncologist.2019-0299.
[27]	Schueler J, Tschuch C, Klingner K, et al. Induction of acquired resistance towards EGFR inhibitor gefitinib in a patient-derived xenograft model of non-small cell lung cancer and subsequent molecular characterization[J]. Cells, 2019,8(7):740. DOI: 10.3390/cells8070740.
[28]	Ichihara E, Harada D, Inoue K, et al. Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors[J]. Cancer Immunol Immunother, 2021,70(1):101-106. DOI: 10.1007/s00262-020-02662-0.
[29]	Lee CK, Man J, Lord S, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis[J]. JAMA Oncol, 2018,4(2):210-216. DOI: 10.1001/jamaoncol.2017.4427.
[30]	Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizu-mab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019,7(5):387-401. DOI: 10.1016/S2213-2600(19)30084-0.
[31]	Pyo KH, Lim SM, Park CW, et al. Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer[J]. J Immunother Cancer, 2020,8(2):e000970. DOI: 10.1136/jitc-2020-000970.